Strengthening Primary Care Pharmacy and Home-Care Medication Support

「The increase in the number of prescriptions due to the effect of new store openings and the increase in prescription prices resulting from prescriptions for high-priced pharmaceuticals contributed to revenue.」

「The number of prescriptions during the fiscal year was 731,726 (692,917 in the previous fiscal year). The generic dispensing rate (annual average) was 89.0% (87.6% in the previous fiscal year), the number of pharmacist-led medication management consultations for designated primary pharmacists was 6,034 (8,882 in the previous fiscal year), and the number of home-care prescriptions was 17,265 (16,682 in the previous fiscal year).」

「Regarding business performance, the number of prescriptions was 106.0% of the level in the same period of the previous year, reflecting an increase centered on new stores opened in the fiscal years ending March 2025 and March 2026. Although we worked to obtain add-on fees for dispensing technology and pharmaceutical management, the average prescription value declined. This was due to an increase in the proportion of medical mall pharmacies, which have lower prescription values, within the Group's dispensing pharmacies, as well as the impact of the drug price revision implemented in April 2025.」

「The number of prescriptions during the consolidated fiscal year under review was 692,917 (653,680 in the previous consolidated fiscal year). The annual average generic dispensing rate was 87.6% (83.6% in the previous consolidated fiscal year), the number of family pharmacist guidance fees claimed was 8,882 (8,981 in the previous consolidated fiscal year), and the number of home prescriptions was 16,682 (15,305 in the previous consolidated fiscal year).」

「Prescription volume was 105.1% year on year due to the effect of new stores opened in the previous consolidated fiscal year and during the interim consolidated accounting period under review. The prescription unit price declined due to the impact of the dispensing fee and drug price revisions implemented in April 2024, but the impact of those revisions was minimized through an increase in prescriptions for high-priced drugs, initiatives involving generic dispensing system add-ons and enhanced services as a “family pharmacy,” as well as efforts to secure technical fee add-ons.」

「Prescription volume was 103.0% year on year, as prescription volume at existing stores continued to recover due to the easing of restrictions on outpatient visits and an increase in patients with infectious diseases, in addition to the effect of new stores opened in the previous consolidated fiscal year. The prescription unit price increased despite the impact of the drug price revision implemented in April 2023, as prescriptions for patients with infectious diseases and high-priced drugs increased and the Group continued to enhance services as a “family pharmacy” and strengthen generic dispensing system add-ons in its efforts to secure dispensing technical fee add-ons.」

「Prescription volume during the second quarter cumulative consolidated accounting period under review was 102.2% year on year, as existing stores showed a recovery trend in addition to the effect of new stores opened in the previous consolidated fiscal year. Although the prescription unit price was affected by the drug price revision implemented in April 2023, it increased as the Group secured dispensing technical fee add-ons through measures including strengthening generic dispensing system add-ons, enhancing services as a “family pharmacy” and benefiting from an increase in prescriptions for high-priced drugs.」

「Prescription volume during the first quarter consolidated accounting period under review was 104.1% year on year, as existing stores showed a recovery trend and benefited from new stores opened in the previous consolidated fiscal year. The prescription unit price declined due to the impact of the drug price revision implemented in April 2023, but the impact of the revision was minimized by the increase in prescriptions for high-priced drugs, enhanced services as a “family pharmacy” and efforts to secure dispensing technical fee add-ons.」

「The number of prescriptions was 108.7% year on year, as prescription volume at existing stores showed a recovery trend in addition to the effect of newly opened stores, despite the continuing impact of COVID-19. Meanwhile, although the Group continued efforts to strengthen generic dispensing system add-on fees and enhance services as a “family pharmacy,” including home healthcare services, the prescription unit price declined due to the impact of the dispensing fee and drug price revisions implemented in April 2022.」

「As a result, the Group achieved results exceeding those of the previous fiscal year for these indicators. (a) Number of prescriptions The number of prescriptions during the consolidated fiscal year under review was 586,064 (555,517 in the previous consolidated fiscal year). (c) Generic dispensing rate The annual average generic dispensing rate during the consolidated fiscal year under review was 81.0% (80.3% in the previous consolidated fiscal year). (d) Number of family pharmacist guidance fees The number of family pharmacist guidance fees claimed during the consolidated fiscal year under review was 6,259 (5,683 in the previous consolidated fiscal year).」

「As a “family pharmacy,” an initiative currently being promoted by the Ministry of Health, Labour and Welfare, the Group centrally and continuously manages medication information, provides guidance and advice on the safe and proper use of prescription drugs, over-the-counter drugs and health foods for individual patients, and offers health consultations. It is also working to provide functions expected of pharmacies, including home medication guidance and 24-hour medication consultations, to realize a “community-based integrated care system” in which people support one another locally so that they can continue living in their familiar communities in their own way until the end of their lives.」